Presently, Omnipod 5 is FDA-cleared in the United States and C.E. marked for use in those with type 1 diabetes aged two years and older. More on the Omnipod 5 Study ...

The Omnipod 5 Automated Insulin Delivery System is now commercially available in Australia, launching soon in Belgium, Canada, and Switzerland. Insulet Corporation (NASDAQ: PODD) (Insulet or the ...

The Omnipod 5 Automated Insulin Delivery System is now commercially available in Australia, launching soon in Belgium, Canada, and Switzerland. Omnipod 5 is now commercially available in Australia ...

Individuals with type 1 diabetes (T1D) have demonstrated improvements in glycaemic control after transitioning away from daily insulin injections to Insult’s Omnipod 5 automated insulin delivery ...

1 The Pod has an IP28 rating for up to 7.6 meters (25 feet) for 60 minutes. The Omnipod 5 Controller is not waterproof. 2 Sherr JL, et al. Diabetes Care (2022). Study in 80 people with type 1 ...

Insulet Corporation PODD announced favorable RADIANT trial clinical data for its Omnipod 5 at the 18th International Conference on Advanced Technologies and Treatments for Diabetes (“ATTD”).

Insulet Corporation, a global leader in tubeless insulin pump technology with its Omnipod brand of products, shared new Omnipod 5 clinical data from its RADIANT study. Results from this multinational ...

Insulet Corporation PODD recently made its Omnipod 5 Automated Insulin Delivery (“AID”) System commercially available in Australia. Omnipod 5 is available with Dexcom G6 and G7 continuous ...